Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

6.00
+0.13002.21%
Volume:29.01K
Turnover:177.61K
Market Cap:103.07M
PE:-5.78
High:6.38
Open:5.89
Low:5.86
Close:5.87
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:1.34
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0377
EPS(LYR):-1.6791
ROE:-240.35%
ROA:-20.88%
PB:6.42
PE(LYR):-3.57

Loading ...

Verrica Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
May 26

Verrica Pharmaceuticals Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
May 26

Lytix Biopharma Q1 net loss widens to NOK 25.95 million

Reuters
·
May 21

Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives

Simply Wall St.
·
May 15

Verrica Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand

Reuters
·
May 13

Verrica Q1 FY26 net loss flat at $9.7 million; revenue rises 46.1% YoY to $5 million

Reuters
·
May 13

Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Estimate

Benzinga
·
May 13

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 13

Verrica Pharmaceuticals Q1 Adjusted EPS USD -0.41

THOMSON REUTERS
·
May 13

Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
May 09

BRIEF-Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data

Reuters
·
May 06

Verrica presents Phase 2 data showing VP-315 shrinks untreated basal cell tumors 67%

Reuters
·
May 06

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of Vp-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (Sid) Annual Meeting

THOMSON REUTERS
·
May 06

Verrica Pharmaceuticals sets conference call for first-quarter 2026 results update

Reuters
·
May 05

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

THOMSON REUTERS
·
May 05

Verrica Pharmaceuticals announces annual shareholder meeting at company headquarters

Reuters
·
Apr 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ)

TIPRANKS
·
Apr 16

Verrica late-breaking Phase 2 VP-315 data suggests abscopal effect in basal cell carcinoma

Reuters
·
Apr 10

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of Vp-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

THOMSON REUTERS
·
Apr 10